Citadel Advisors
SLXN

Citadel Advisors’s Silexion Therapeutics SLXN Stock Holding History

Citadel Advisors’s Portfolio SLXN Stock Details SLXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-2,093
Closed -$26.8K – 15124
2026
Q1 		$26.8K Buy
2,093
+872
+71% +$15.3K ﹤0.01% 12607
2025
Q4 		$23.4K Buy
+1,221
New +$36.7K ﹤0.01% 12303

Other funds holding SLXN

HF
HRT Financial New York $54.8B AUM 81.03% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
MA
Montag & Associates Atlanta, Georgia $2.37B AUM 28.86% 1-Year Est. Return
PK
Pflug Koory Omaha, Nebraska $250M AUM 42.29% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Citadel Advisors's SLXN Position: Q2 2026 in Review

Citadel Advisors sold out of Silexion Therapeutics (SLXN) in Q2 2026, closing a stake of 2,093 shares — an estimated $26.8K sold.

Citadel Advisors first reported a position in SLXN in Q4 2025 and held it in 2 quarters. The position peaked at $26.8K in Q1 2026. 6 funds tracked by Wall St. Rank hold SLXN as of Q2 2026.

  • Citadel Advisors reported no remaining Silexion Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Citadel Advisors sold 2,093 Silexion Therapeutics shares in Q2 2026, an estimated $26.8K.
  • Citadel Advisors first reported a position in Silexion Therapeutics in Q4 2025 and held it in 2 quarters.
  • Citadel Advisors's Silexion Therapeutics position peaked at $26.8K in Q1 2026.
  • 6 funds tracked by Wall St. Rank held Silexion Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.